Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Publication

February 6, 2023

Google LLC v. IPA Technologies Inc., 34 F.4th 1081 (Fed. Cir. 2022) (Dyk, Schall, Taranto)

Sterne, Kessler, Goldstein & Fox

Articles

February 6, 2023

Data and Trends: AIA PTAB Appeals to the Federal Circuit

Sterne, Kessler, Goldstein & Fox

Articles

February 6, 2023

Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc., 25 F.4th 998 (Fed. Cir. 2022) (Newman, Lourie, Stoll)

Sterne, Kessler, Goldstein & Fox